Dr. Feng’s clinical interests include the diagnosis and management of genitourinary malignancies. He specializes in the treatment of high-risk aggressive prostate cancers as well as oligometastatic disease. For upfront or post-surgical treatment for patients, his therapeutic approaches include intensity-modulated radiation therapy as well as stereotactic ablative radiotherapy, among many others. Dr. Feng is nationally known for his approaches of using molecular biomarkers to help guide or personalize radiation therapy for patients. He serves as the leader of the Genitouirnary Cancer Translational Research Program for the NRG Clinical Trials Group, and is a member of the National Cancer Institute Steering Committee for Genitourinary Cancers. He has helped conduct numerous clinical trials, and is the co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer.